CN111595985A - Analytical method for measuring related substances of rebamipide by using HPLC (high performance liquid chromatography) - Google Patents

Analytical method for measuring related substances of rebamipide by using HPLC (high performance liquid chromatography) Download PDF

Info

Publication number
CN111595985A
CN111595985A CN202010655949.0A CN202010655949A CN111595985A CN 111595985 A CN111595985 A CN 111595985A CN 202010655949 A CN202010655949 A CN 202010655949A CN 111595985 A CN111595985 A CN 111595985A
Authority
CN
China
Prior art keywords
impurity
rebamipide
minutes
mobile phase
equal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN202010655949.0A
Other languages
Chinese (zh)
Other versions
CN111595985B (en
Inventor
侯叶婷
董梦飞
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Suzhou Zhengji Pharmaceutical Co ltd
Original Assignee
Suzhou Zhengji Pharmaceutical Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Suzhou Zhengji Pharmaceutical Co ltd filed Critical Suzhou Zhengji Pharmaceutical Co ltd
Priority to CN202010655949.0A priority Critical patent/CN111595985B/en
Publication of CN111595985A publication Critical patent/CN111595985A/en
Application granted granted Critical
Publication of CN111595985B publication Critical patent/CN111595985B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02Column chromatography
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02Column chromatography
    • G01N30/26Conditioning of the fluid carrier; Flow patterns
    • G01N30/28Control of physical parameters of the fluid carrier
    • G01N30/34Control of physical parameters of the fluid carrier of fluid composition, e.g. gradient
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02Column chromatography
    • G01N30/86Signal analysis
    • G01N30/8624Detection of slopes or peaks; baseline correction
    • G01N30/8631Peaks
    • G01N30/8634Peak quality criteria
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02Column chromatography
    • G01N30/86Signal analysis
    • G01N30/8624Detection of slopes or peaks; baseline correction
    • G01N30/8631Peaks
    • G01N30/8637Peak shape

Landscapes

  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Quality & Reliability (AREA)
  • Engineering & Computer Science (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

The invention relates to the technical field of analytical chemistry, and discloses an analytical method for determining related substances of rebamipide by using HPLC. The analysis method provided by the invention is characterized in that a reversed phase chromatographic column with octadecylsilane chemically bonded silica as a filler, a buffer salt solution as a mobile phase A and a buffer salt solution, methanol and tetrahydrofuran as a mobile phase B are used for carrying out gradient elution on a sample solution of rebamipide and carrying out HPLC analysis. The analysis method can effectively separate rebamipide and related substances thereof, so that impurity peaks and rebamipide peaks are not overlapped, the peak shape is good, the separation requirement is met, and the method is suitable for controlling related substances and researching impurities.

Description

Analytical method for measuring related substances of rebamipide by using HPLC (high performance liquid chromatography)
Technical Field
The invention relates to the technical field of analytical chemistry, in particular to an analytical method for determining related substances of rebamipide by using HPLC.
Background
Rebamipide (±)2- (4-chlorobenzamide) -3- [2(1H) -quinolinone-4]Propionic acid is a prostaglandin derivative, is a novel gastric mucosa protective agent, and has the CAS number: 90098-04-7 with molecular formula C19H15ClN2O4The molecular weight is: 370.79, the chemical structure is:
Figure BDA0002576738290000011
rebamipide is an anti-ulcer drug developed by tsukamur pharmaceutical company of japan, since 1990
Figure BDA0002576738290000012
The trade name is first marketed in japan as an oral protective antiulcer drug. Preventing and treating peptic ulcer by strengthening the defense function of gastric mucosa; can increase prostaglandin content in gastric mucosa, increase blood flow of gastric mucosa, and increase gastric mucus; can inhibit gastric reverse diffusion and promote gastric alkali secretion; eliminating and inhibiting active oxygen, and maintaining gastric mucosa superoxide dismutase (SOD) activity. The composition can be used for preventing and treating acute and chronic gastric ulcer, and also can be used for preventing damage of various injury factors (such as sodium hydroxide, hydrochloric acid, acetic acid, and non-steroidal anti-inflammatory drug) to gastric mucosa. Meanwhile, the medicine has regenerative and uniform repair effect on gastric mucosa tissues, can reduce the cure recurrence rate of gastric ulcer, which is not possessed by various anti-ulcer medicines used at present.
At present, the quality control of related substances of rebamipide is recorded in pharmacopoeia, but impurities generated in the following 4 technological synthesis processes cannot be considered in one analysis method:
impurity A: 2-amino-3- (2-oxo-1, 2-dihydroquinolin-4-yl) propionic acid;
Figure BDA0002576738290000013
impurity B: 2- (2-chlorobenzoylamino) -3- (1, 2-dihydro-2-oxo-4-quinolinyl) propionic acid;
Figure BDA0002576738290000021
impurity C: 2- (3-chlorobenzoylamino) -3- (1, 2-dihydro-2-oxo-4-quinolinyl) propionic acid;
Figure BDA0002576738290000022
impurity D: 2- (3, 4-dichlorobenzamido) -3- (1, 2-dihydro-2-oxo-4-quinolinyl) propionic acid;
Figure BDA0002576738290000023
therefore, it is required to provide an efficient HPLC method for analyzing and detecting related substances of rebamipide.
Disclosure of Invention
In view of the above, it is an object of the present invention to provide an analytical method for determining rebamipide-related substances by HPLC, which is capable of efficiently separating 2-amino-3- (2-oxo-1, 2-dihydroquinolin-4-yl) propionic acid, 2- (2-chlorobenzoylamino) -3- (1, 2-dihydro-2-oxo-4-quinolyl) propionic acid, 2- (3-chlorobenzoylamino) -3- (1, 2-dihydro-2-oxo-4-quinolyl) propionic acid and 2- (3, 4-dichlorobenzoylamino) -3- (1, 2-dihydro-2-oxo-4-quinolyl) propionic acid, so that impurity peaks and rebamipide peaks are not overlapped, the peak shape is good and the separation requirement is met.
In order to achieve the above purpose, the invention provides the following technical scheme:
an analytical method for determining related substances of rebamipide by HPLC (high performance liquid chromatography), which is characterized in that a reverse phase chromatographic column with octadecylsilane chemically bonded silica as a filler, a buffer salt solution as a mobile phase A and a buffer salt solution, methanol and tetrahydrofuran as a mobile phase B are used, and a sample solution of rebamipide is subjected to gradient elution and HPLC analysis.
Preferably, the volume ratio of the buffer salt solution, the methanol and the tetrahydrofuran in the mobile phase B is (0-40): (54-90): (6-10). When the buffered salt solution is other than 0, it is more advantageous for the column. In a specific embodiment of the invention, the mobile phase B is a buffered salt solution, methanol and tetrahydrofuran in a volume ratio of 40:54: 6; or methanol and tetrahydrofuran in a volume ratio of 90: 10.
Preferably, the buffered salt solution is a phosphate buffer solution, the concentration of the phosphate buffer solution is between 0.005M and 0.05M, and the pH value is between 6.2 and 6.8. More preferably, the buffered salt solution is one of a potassium dihydrogen phosphate solution and a sodium dihydrogen phosphate solution, and the preparation method refers to the method in pharmacopoeia. In a specific embodiment of the invention, the buffered salt solution has a concentration of 0.05M potassium dihydrogen phosphate at a pH of 6.5.
Preferably, the gradient elution procedure is as follows in table 1:
TABLE 1
Elution time (minutes) Mobile phase A (%) Mobile phase B (%)
0 90~10 10~90
A 90~10 10~90
B 50~0 50~100
C 50~0 50~100
D 90~10 10~90
E 90~10 10~90
Wherein A is more than 0 and less than or equal to 30 minutes, B is more than 30 and less than or equal to 45 minutes, C is more than 45 and less than or equal to 55 minutes, D is more than 55 and less than or equal to 58 minutes, and E is more than 58 and less than or equal to 70 minutes.
In a specific embodiment of the invention, the gradient elution procedure shown in table 1 can be referred to table 3:
TABLE 3
Elution time Mobile phase A (%) Mobile phase B (%)
0min 60 40
25min 60 40
40min 40 60
54min 40 60
56min 60 40
60min 60 40
Preferably, the gradient elution procedure is as follows in table 2:
TABLE 2
Elution time (minutes) Mobile phase A (%) Mobile phase B (%)
0 70~20 30~80
A 70~20 30~80
B 30~0 0~100
C 30~0 0~100
D 70~20 30~80
E 70~20 30~80
Wherein A is more than 0 and less than or equal to 25 minutes, B is more than 25 and less than or equal to 40 minutes, C is more than 40 and less than or equal to 55 minutes, D is more than 55 and less than or equal to 58 minutes, and E is more than 58 and less than or equal to 60 minutes.
In a specific embodiment of the present invention, the gradient elution procedure shown in table 2 can be referred to table 4:
TABLE 4
Elution time Mobile phase A (%) Mobile phase B (%)
0min 33 67
25min 33 67
40min 0 100
54min 0 100
56min 33 67
60min 33 67
Preferably, the reversed phase chromatographic column is a chromatographic column with the filler particle diameter of between 3.0 and 5.0 microns, the chromatographic column length of between 150 and 250mm and the chromatographic column diameter of between 2.0 and 4.6 mm. In the specific embodiment of the invention, the reversed phase chromatographic column is a chromatographic column which takes octadecylsilane chemically bonded silica as a filler, the particle size is 5.0 μm, the length of the chromatographic column is 250mm, and the diameter of the chromatographic column is 4.6 nm; for example Kromasil100-5c 184.6 mm x 250mm, 5 μm.
Preferably, the HPLC detection wavelength is 235nm, the column temperature is 40 ℃, and the flow rate is 0.8 ml/min.
The invention uses different analysis methods to carry out HPLC analysis on the same sample solution preparation formulation, and the result shows that the impurities A-D and rebamipide can be effectively separated under the analysis method of the invention, and the peak shapes are good and have no overlapping; and the HPLC results of other mobile phases show that part of impurity peaks and rebamipide peaks do not meet the separation requirement, and part of impurity peaks are split into two peaks.
According to the technical scheme, the analysis method provided by the invention adopts a reversed phase chromatographic column with octadecylsilane chemically bonded silica as a filler, adopts a buffer salt solution as a mobile phase A, adopts a buffer salt solution, methanol and tetrahydrofuran as a mobile phase B, and performs gradient elution on a sample solution of rebamipide and performs HPLC analysis. The analysis method can effectively separate rebamipide and related substances thereof, so that impurity peaks and rebamipide peaks are not overlapped, the peak shape is good, the separation requirement is met, and the method is suitable for control of related substances and research on impurities.
Drawings
Fig. 1 shows the HPLC detection result of example 1, where RT-8.733 min is the peak of impurity a, RT-6.796 min is the peak of impurity B, RT-24.9 min is the peak of impurity D, RT-12.159 min is the peak of rebamipide, the peak of impurity C is not detected, and the impurity C overlaps with the rebamipide peak;
fig. 2 shows the HPLC detection result of example 2, where RT-7.097 min is the peak of impurity B, RT-19.668 min is the peak of impurity C, RT-20.897 min is the peak of rebamipide, RT-36.779 min is the peak of impurity D, and impurity a splits into two peaks;
fig. 3 is a result of HPLC detection in example 3, where RT ═ 3.302min is a peak of impurity a, RT ═ 6.096min is a peak of impurity B, RT ═ 11.496min is a peak of impurity C, RT ═ 11.917min is a peak of rebamipide, RT ═ 24.623min is a peak of impurity D, and the peaks of impurity C and rebamipide do not meet the separation requirement;
fig. 4 shows the HPLC detection result of example 4, where RT-3.153 min is the peak of impurity a, RT-7.848 min is the peak of impurity B, RT-19.756 min is the peak of impurity C, RT-21.014 min is the peak of rebamipide, and RT-39.146 min is the peak of impurity D;
fig. 5 shows the HPLC detection result of example 5, where RT ═ 3.168min is the peak of impurity a, RT ═ 7.892min is the peak of impurity B, RT ═ 19.788min is the peak of impurity C, RT ═ 20.607min is the peak of rebamipide, and RT ═ 39.177min is the peak of impurity D.
Detailed Description
The embodiment of the invention discloses an analysis method for measuring related substances of rebamipide by using HPLC (high performance liquid chromatography), and a person skilled in the art can realize the analysis by properly improving process parameters by referring to the content. It is expressly intended that all such similar substitutes and modifications which would be obvious to those skilled in the art are deemed to be included within the invention. While the assay methods of the present invention have been described in terms of preferred embodiments, it will be apparent to those of ordinary skill in the art that variations and modifications of the assay methods described herein, as well as suitable variations and combinations of methods, may be made to implement and use the techniques of the present invention without departing from the spirit and scope of the invention.
The chemical names and structural formulas of the impurity A, the impurity B, the impurity C and the impurity D are as follows:
impurity A: 2-amino-3- (2-oxo-1, 2-dihydroquinolin-4-yl) propionic acid;
Figure BDA0002576738290000061
impurity B: 2- (2-chlorobenzoylamino) -3- (1, 2-dihydro-2-oxo-4-quinolinyl) propionic acid;
Figure BDA0002576738290000062
impurity C: 2- (3-chlorobenzoylamino) -3- (1, 2-dihydro-2-oxo-4-quinolinyl) propionic acid;
Figure BDA0002576738290000063
impurity D: 2- (3, 4-dichlorobenzamido) -3- (1, 2-dihydro-2-oxo-4-quinolinyl) propionic acid;
Figure BDA0002576738290000064
in a specific embodiment of the present invention, the present invention provides the following two examples to describe the analytical method of the present invention:
(1) preparing a sample into a solution containing rebamipide and a proper amount of impurities, detecting on a reversed-phase high performance liquid chromatograph by referring to a high performance liquid chromatography, analyzing by using a chromatographic column with octadecylsilane chemically bonded silica as a filler, the particle size of the chromatographic column being 5.0 mu M, the length of the chromatographic column being 250mm and the diameter of the chromatographic column being 4.6mm, and performing gradient elution under a mobile phase system with 0.05M phosphate buffer solution, pH 6.5 as a mobile phase A and methanol-tetrahydrofuran (90:10) as a mobile phase B, wherein the elution gradient is shown in Table 3; detecting at 235nm, 40 deg.C, and 0.8ml/min flow rate, injecting 20ul of sample solution into liquid chromatograph, and recording chromatogram.
(2) Preparing a sample into a solution containing rebamipide and a proper amount of impurities, detecting on a reversed-phase high performance liquid chromatograph by referring to a high performance liquid chromatography, using octadecylsilane chemically bonded silica as a filler, and performing analysis on a chromatographic column with the particle size of 5.0 mu M, the length of the chromatographic column of 250mm and the diameter of the chromatographic column of 4.6mm, and performing gradient elution under a mobile phase system which uses 0.05M phosphate buffer solution, the pH of which is 5.5 as a mobile phase A, and uses phosphate buffer salt-methanol-tetrahydrofuran (40:54:6) to adjust the pH value to 6.5 by using phosphoric acid as a mobile phase B, wherein the elution gradient is shown in Table 4; the detection wavelength is 235nm, the column temperature is 40 ℃, and the flow rate is 0.8 ml/min; and (4) injecting 20ul of the test solution into a liquid chromatograph, and recording the chromatogram.
In the comparative tests, unless otherwise specified, the various test conditions were consistent with the examples, except for the differences noted.
The analytical method for determining rebamipide related substances by HPLC provided by the present invention is further described below.
Example 1: control HPLC analytical method
High performance liquid chromatograph: shimadzu;
a chromatographic column: senecio CAPCELL PAK UG 120250 4.6mm 5 μm;
mobile phase: 2.44g of 1-sodium decane sulfonate is dissolved by 1000ml of water, and then 1000ml of methanol and 10ml of phosphoric acid are added;
detection wavelength: 232 nm;
flow rate: adjusting the flow rate so that the retention time of rebamipide is about 12 minutes;
column temperature: 25 ℃;
sample introduction amount: 10 mu l of the mixture;
isocratic elution;
preparing a mixed solution: taking appropriate amount of rebamipide, impurity A, impurity B, impurity C and impurity D, dissolving and diluting with diluent [ 0.05mol/L phosphate buffer solution-methanol (7:7:6) with water-pH6.0 ] to obtain solution containing rebamipide 0.4mg, impurity A, impurity B, impurity C and impurity D0.04 mg respectively per 1ml, and shaking up.
And (3) detection results: as a result, referring to fig. 1, it can be seen that in this example, RT-8.733 min is the peak of impurity a, RT-6.796 min is the peak of impurity B, RT-24.9 min is the peak of impurity D, RT-12.159 min is the peak of rebamipide, and the peak of impurity C is not detected and overlaps with the peak of rebamipide.
Example 2: control HPLC analytical method
High performance liquid chromatograph: shimadzu;
a chromatographic column: wakopak Wakosil-II 3 C184.6mm 150 mm;
mobile phase A: phosphate buffer solution with pH of 6.2 (9.08 g of monopotassium phosphate is weighed and dissolved by 1000ml of water, 9.46g of anhydrous disodium hydrogen phosphate is weighed and dissolved by 1000ml of water, 800ml of potassium dihydrogen phosphate solution is taken and 200ml of disodium hydrogen phosphate solution is taken to be uniformly mixed, if necessary, the pH is adjusted to 6.2 by the potassium dihydrogen phosphate solution or the disodium hydrogen phosphate solution), 300ml of water is added and uniformly mixed;
mobile phase B: acetonitrile;
detection wavelength: 222 nm;
column temperature: 25 ℃;
sample introduction amount: 10 mu l of the mixture;
gradient elution: the flow rate was adjusted so that the rebamipide retention time was about 20 minutes, see table 5.
TABLE 5
Elution time Mobile phase A (%) Mobile phase B (%)
0min 83 17
30min 83 17
33min 60 40
38min 60 40
40min 83 17
45min 83 17
Preparing a mixed solution: taking appropriate amount of rebamipide, impurity A, impurity B, impurity C and impurity D, dissolving and diluting with diluent [ 0.05mol/L phosphate buffer solution-methanol (7:7:6) with water-pH6.0 ] to obtain solution containing rebamipide 0.4mg, impurity A, impurity B, impurity C and impurity D0.04 mg respectively per 1ml, and shaking up.
And (3) detection results: referring to fig. 2, it can be seen that in this example, RT-7.097 min is the peak of impurity B, RT-19.668 min is the peak of impurity C, RT-20.897 min is the peak of rebamipide, RT-36.779 min is the peak of impurity D, and impurity a splits into two peaks.
Example 3: control HPLC analytical method
High performance liquid chromatograph: agilent 1260;
a chromatographic column: kromasil100-5 C184.6mm 250mm, 5 μm;
mobile phase: methanol: phosphate buffer (potassium dihydrogen phosphate 6.8g, 152ml with 0.1mol/L sodium hydroxide solution, 20ml with tetrabutylammonium hydroxide 10% aqueous solution, diluted to 1000ml with water, pH adjusted to 6.5 with phosphoric acid) 52: 48;
detection wavelength: 235 nm;
flow rate: 0.8 ml/min;
column temperature: 40 ℃;
sample introduction amount: 20 mu l of the mixture;
isocratic elution;
preparing a mixed solution: taking appropriate amount of rebamipide, impurity A, impurity B, impurity C and impurity D, dissolving and diluting with mobile phase to obtain solution containing rebamipide 0.2mg, impurity A, impurity B, impurity C and impurity D0.02 mg respectively per 1ml, and shaking up.
And (3) detection results: as a result, referring to fig. 3, it can be seen that in this example, RT ═ 3.302min is the peak of impurity a, RT ═ 6.096min is the peak of impurity B, RT ═ 11.496min is the peak of impurity C, RT ═ 11.917min is the peak of rebamipide, RT ═ 24.623min is the peak of impurity D, and the peaks of impurity C and rebamipide do not meet the separation requirement.
Example 4: HPLC analysis method of the present invention
High performance liquid chromatograph: agilent 1260;
a chromatographic column: kromasil100-5 C184.6mm 250mm, 5 μm;
mobile phase A: phosphate buffer solution [ potassium dihydrogen phosphate 6.8g, adding 0.1mol/L sodium hydroxide solution 152ml, adding 20ml tetrabutylammonium hydroxide 10% water solution, diluting with water to 1000ml, adjusting pH to 6.5 with phosphoric acid ];
mobile phase B: methanol-tetrahydrofuran (90: 10);
detection wavelength: 235 nm;
flow rate: 0.8 ml/min;
column temperature: 40 ℃;
sample introduction amount: 20 mu l of the mixture;
gradient elution: table 3;
preparing a mixed solution: dissolving appropriate amount of rebamipide, impurity A, impurity B, impurity C, and impurity D with diluent [ mobile phase A-mobile phase B (60:40) ] and diluting to obtain solution containing rebamipide 0.2mg, impurity A, impurity B, impurity C, and impurity D0.02 mg respectively per 1ml, and shaking
And (3) detection results: referring to fig. 4, it can be seen that in this example, RT-3.153 min is the peak of impurity a, RT-7.848 min is the peak of impurity B, RT-19.756 min is the peak of impurity C, RT-21.014 min is the peak of rebamipide, and RT-39.146 min is the peak of impurity D. The mobile phase A, B (40:60) mixture was at a pH of about 7.6, which was detrimental to the chromatography column.
Example 5: HPLC analysis method of the present invention
High performance liquid chromatograph: agilent 1260;
a chromatographic column: kromasil100-5 C184.6mm 250mm, 5 μm;
mobile phase A: phosphate buffer solution [ potassium dihydrogen phosphate 6.8g, adding 0.1mol/L sodium hydroxide solution 152ml, adding 20ml tetrabutylammonium hydroxide 10% water solution, diluting with water to 1000ml, adjusting pH to 6.5 with phosphoric acid ];
mobile phase B: phosphate buffer-methanol-tetrahydrofuran (40:54:6) was adjusted to pH 6.5 detection wavelength with phosphoric acid: 235 nm;
flow rate: 0.8 ml/min;
column temperature: 40 ℃;
sample introduction amount: 20 mu l of the mixture;
gradient elution: table 4;
preparing a mixed solution: taking appropriate amount of rebamipide, impurity A, impurity B, impurity C and impurity D, dissolving and diluting with diluent (mobile phase A-methanol-tetrahydrofuran (60: 36: 4)) to obtain solution containing 1.0mg of rebamipide, 1.5ug/ml of impurity A, 1.5ug/ml of impurity B and 1.0ug/ml of impurity D per 1ml, and shaking up.
And (3) detection results: referring to fig. 5, it can be seen that in this example, RT ═ 3.168min is the peak of impurity a, RT ═ 7.892min is the peak of impurity B, RT ═ 19.788min is the peak of impurity C, RT ═ 20.607min is the peak of rebamipide, and RT ═ 39.177min is the peak of impurity D.
The foregoing is only for the purpose of understanding the method of the present invention and the core concept thereof, and it will be understood by those skilled in the art that various changes and modifications may be made without departing from the principle of the invention, and the invention also falls within the scope of the appended claims.

Claims (7)

1. An analytical method for measuring related substances of rebamipide by using HPLC is characterized in that a reverse phase chromatographic column using octadecylsilane chemically bonded silica as a filler, a buffer salt solution as a mobile phase A, a buffer salt solution, methanol and tetrahydrofuran as a mobile phase B are used, and a sample solution of rebamipide is subjected to gradient elution and HPLC analysis.
2. The assay of claim 1: the method is characterized in that the buffer salt solution is phosphate buffer solution, the concentration of the phosphate buffer solution is between 0.005M and 0.05M, and the pH value is between 6.2 and 6.8.
3. The analytical method of claim 1, wherein the volume ratio of the buffer salt solution, methanol and tetrahydrofuran in the mobile phase B is (0-40): (54-90): (6-10).
4. The assay of claim 1, wherein the gradient elution procedure is as follows in table 1:
TABLE 1
Elution time (minutes) Mobile phase A (%) Mobile phase B (%) 0 90~10 10~90 A 90~10 10~90 B 50~0 50~100 C 50~0 50~100 D 90~10 10~90 E 90~10 10~90
Wherein A is more than 0 and less than or equal to 30 minutes, B is more than 30 and less than or equal to 45 minutes, C is more than 45 and less than or equal to 55 minutes, D is more than 55 and less than or equal to 58 minutes, and E is more than 58 and less than or equal to 70 minutes.
5. The assay of claim 1 or 4, wherein the gradient elution procedure is as follows in Table 2:
TABLE 2
Figure FDA0002576738280000011
Figure FDA0002576738280000021
Wherein A is more than 0 and less than or equal to 25 minutes, B is more than 25 and less than or equal to 40 minutes, C is more than 40 and less than or equal to 55 minutes, D is more than 55 and less than or equal to 58 minutes, and E is more than 58 and less than or equal to 60 minutes.
6. The analytical method of claim 1, wherein the reverse phase chromatography column is a column having a packing particle size of 3.0 μm to 5.0 μm, a column length of 150mm to 250mm, and a column diameter of 2.0mm to 4.6 mm.
7. The analytical method according to claim 1, wherein the HPLC detection wavelength is 235nm, the column temperature is 40 ℃, and the flow rate is 0.8 ml/min.
CN202010655949.0A 2020-07-09 2020-07-09 Analytical method for measuring related substances of rebamipide by using HPLC (high performance liquid chromatography) Active CN111595985B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202010655949.0A CN111595985B (en) 2020-07-09 2020-07-09 Analytical method for measuring related substances of rebamipide by using HPLC (high performance liquid chromatography)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202010655949.0A CN111595985B (en) 2020-07-09 2020-07-09 Analytical method for measuring related substances of rebamipide by using HPLC (high performance liquid chromatography)

Publications (2)

Publication Number Publication Date
CN111595985A true CN111595985A (en) 2020-08-28
CN111595985B CN111595985B (en) 2022-03-29

Family

ID=72189282

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202010655949.0A Active CN111595985B (en) 2020-07-09 2020-07-09 Analytical method for measuring related substances of rebamipide by using HPLC (high performance liquid chromatography)

Country Status (1)

Country Link
CN (1) CN111595985B (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112798728A (en) * 2020-12-30 2021-05-14 日照正济药业有限公司 Chromatographic analysis method for separating rebamipide and m-chloroprebamipide
CN112816585A (en) * 2020-12-30 2021-05-18 苏州正济药业有限公司 Method for detecting rebamipide and related substances thereof
CN115524417A (en) * 2022-09-19 2022-12-27 杭州沐源生物医药科技有限公司 Analysis method of related substances and isomers of rebamipide tablets

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102174015A (en) * 2011-03-07 2011-09-07 江西同和药业有限责任公司 Refining method of rebamipide
CN103076421A (en) * 2012-12-31 2013-05-01 北京元延医药科技有限公司 Analytic method for related substance examination of rebamipide
CN104662004A (en) * 2012-06-26 2015-05-27 三进制药株式会社 Novel rebamipide prodrug, method for producing same, and usage thereof
CN110426463A (en) * 2019-07-08 2019-11-08 苏州天马药业有限公司 Detection method in relation to substance in a kind of p-chlorobenzamido diethyl malonate sample

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102174015A (en) * 2011-03-07 2011-09-07 江西同和药业有限责任公司 Refining method of rebamipide
CN104662004A (en) * 2012-06-26 2015-05-27 三进制药株式会社 Novel rebamipide prodrug, method for producing same, and usage thereof
CN103076421A (en) * 2012-12-31 2013-05-01 北京元延医药科技有限公司 Analytic method for related substance examination of rebamipide
CN110426463A (en) * 2019-07-08 2019-11-08 苏州天马药业有限公司 Detection method in relation to substance in a kind of p-chlorobenzamido diethyl malonate sample

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
SAMAH S.ABBAS ET AL: "Stability-Indicating Determination of Rebamipide in the Presence of its Acid Degradation Products", 《JOURNAL OF AOAC INTERNATIONAL》 *
李国锋 等: "HPLC梯度洗脱法测定大鼠血清和结肠组织中瑞巴派特的浓度", 《中国药房》 *
汪大海: "高效液相色谱法测定瑞巴派特片含量", 《中国药师》 *
陈英华 等: "瑞巴派特有关物质分析方法的探讨", 《河北化工》 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112798728A (en) * 2020-12-30 2021-05-14 日照正济药业有限公司 Chromatographic analysis method for separating rebamipide and m-chloroprebamipide
CN112816585A (en) * 2020-12-30 2021-05-18 苏州正济药业有限公司 Method for detecting rebamipide and related substances thereof
CN115524417A (en) * 2022-09-19 2022-12-27 杭州沐源生物医药科技有限公司 Analysis method of related substances and isomers of rebamipide tablets

Also Published As

Publication number Publication date
CN111595985B (en) 2022-03-29

Similar Documents

Publication Publication Date Title
CN111595985B (en) Analytical method for measuring related substances of rebamipide by using HPLC (high performance liquid chromatography)
CN110426463B (en) Method for detecting related substances in p-chlorobenzoylamino diethyl malonate sample
TWI759575B (en) Test method for related substances derived from trifluorothymidine
CN107831230B (en) Method for separating and determining related impurities in atorvastatin and preparation thereof
Tanaka et al. Direct HPLC separation of enantiomers of pantoprazole and other benzimidazole sulfoxides using cellulose‐based chiral stationary phases in reversed‐phase mode
CN106706768B (en) Method for separating and measuring empagliflozin and related substances thereof
CN113906022A (en) Pyrazolopyridines and triazolopyridines as A2A/A2B inhibitors
CN107703235B (en) Supercritical fluid chromatographic separation method for lenalidomide enantiomer
JP4236463B2 (en) Process for producing optically active ethyl (3R, 5S, 6E) -7- [2-cyclopropyl-4- (4-fluorophenyl) quinolin-3-yl] -3,5-dihydroxy-6-heptenoate
JPH07506591A (en) 8-substituted xanthines as phosphodiesterase inhibitors
CN111239299B (en) Method for separating and measuring palbociclib and impurities thereof
CN106478600A (en) A kind of process for purification of Lansoprazole
JP2002501896A (en) S-lansoprazole compositions and methods
CN103202816A (en) Pantoprazole sodium freeze-dried powder injection
RU2596823C2 (en) DERIVATIVES OF 7-(HETEROARYL-AMINO)-6,7,8,9-TETRAHYDROPYRIDO[1,2-a]INDOLE-ACETIC ACID AND USE THEREOF AS PROSTAGLANDIN D2 RECEPTOR MODULATORS
JP2002512263A (en) S-Raybprazole compositions and methods
CN112034066B (en) Method for separating and measuring Ribociclib and impurities
CN115524417B (en) Analysis method of rebamipide tablet related substances and isomers
Ali et al. Development and validation for RP-HPLC method of assay of omeprazole capsules formulation
TW202144329A (en) Crystal form of nitroxoline prodrug, pharmaceutical composition containing the same, and preparation method and application thereof
CN109879938B (en) Preparation method of ganirelix acetate
CN114929700A (en) Pharmaceutical composition of tricyclic PDE3/PDE4 dual inhibitor compound
CN112540128A (en) Method for measuring chlorpheniramine maleate intermediate and related substances thereof by liquid phase separation
CN107305199B (en) Method for separating and measuring two components and related substances in compound nasal spray of azelastine hydrochloride and fluticasone propionate
CN113648284B (en) Tablet containing Sacubitril valsartan sodium and preparation method thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant